TXMD

TherapeuticsMD ($TXMD) CEO Buys Shares Same Day Company Sues Mayne Pharma for Contract Breach—Confidence Signal or Concerning Timing?

04/10/2025 20:36

TherapeuticsMD Inc ($TXMD) CEO Marlan D Walker has recently made consecutive purchases of company stock, coinciding precisely with the company's filing of a breach of contract lawsuit against its business partner Mayne Pharma. On April 9 and April 10, 2025, Walker purchased 1,136 and 1,167 shares at average prices of $0.87 and $0.86, respectively. Though modest in dollar value at approximately $994 and $1,000, these insider buys stand out because they occurred exactly as the company initiated legal action against a key business partner and while the stock trades below the $1 threshold. TherapeuticsMD, a pharmaceutical royalty company with a market capitalization of just $10.3 million, has transformed its business model after selling its women's health product business to Mayne Pharma in 2022, retaining royalty rights to these products. The company's portfolio includes IMVEXXY (for menopause-related vaginal pain), BIJUVA (for menopausal symptoms), and ANNOVERA (a contraceptive device). Interestingly, in July 2024, Mayne Pharma sued Indian drugmaker Sun Pharma for patent infringement related to IMVEXXY, alleging violations of all 20 Orange Book-listed patents associated with the product. Now, TherapeuticsMD has turned around and sued Mayne Pharma itself for breach of contract, though specific details of the alleged breach remain undisclosed. This litigation pattern suggests deteriorating business relationships that could significantly impact $TXMD's revenue stream. The stock has struggled considerably, dropping from $2.21 in early June 2024 to its current level around $0.89, representing a year-over-year decline of approximately 58%. The share price has experienced notable volatility, particularly at the turn of the year when it jumped from $0.86 on December 31, 2024, to $1.57 on January 2, 2025, before resuming its downward trajectory. TherapeuticsMD's financial situation remains precarious. For the fiscal year ended December 31, 2024, the company reported revenue of just $1.76 million and a net loss of $2.31 million, resulting in a staggering profit margin of -123.85%. On a positive note, quarterly revenue growth was 32.90% year-over-year, and the company maintains $5.06 million in cash with a healthy current ratio of 2.37, providing some near-term liquidity. The company's valuation metrics present a mixed picture. With a price-to-book ratio of 0.37, the stock trades below its book value, potentially indicating undervaluation. However, its price-to-sales ratio stands at 5.76, which is relatively high for a company with ongoing losses and facing legal challenges. Prior to the CEO's recent purchases, Director Cooper C Collins made similar moves, buying 1,200 shares at $1.70 on August 21, 2024, followed by 4,094 shares at $1.73 the next day. These earlier insider purchases also failed to reverse the stock's downward momentum, though they occurred at nearly double the current share price. For investors, the CEO's stock purchases amid legal action against Mayne Pharma create a complex situation. While insider buying typically signals management confidence, the modest dollar amount and concurrent legal dispute with a key business partner raise significant questions about TherapeuticsMD's future revenue prospects and business stability.

You can receive notifications when news is published.